Papillary Thyroid Cancer Clinical Trial
Official title:
Caratterizzazione Del Profilo Mutazionale Nel Tumore Papillare Della Tiroide Tramite Tecnologia Mass-ARRAY
Somatic mutations in the MAP (mitogen-activated protein) kinase pathway have been found in about 80% of papillary thyroid tumors (PTCs). The evaluation of the PTC mutational profile is crucial for the definition of the prognosis and for predicting the effects of targeted and personalized therapies. Molecular characterization by mass spectrometry (Mass ARRAY) allows the search for multiple mutations in a single experiment, in a sensitive, fast and economic way. A Mass ARRAY platform (PTC-MA) was developed, capable of identifying the presence of the most common somatic point mutations and rearrangements in PTC (Pesenti et al., Endocrine 2017). The aim of the study is to characterize the mutational profile of a large series of papillary thyroid carcinomas (PTC). Tumor samples will be analyzed using our PTC-MA platform. The molecular profile of PTCs will be correlated with the clinical and prognostic characteristics of the patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01441154 -
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
|
||
| Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT03469011 -
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
|
Phase 1 | |
| Recruiting |
NCT05752669 -
Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.
|
||
| Recruiting |
NCT04076514 -
The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma
|
||
| Completed |
NCT06439745 -
More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
|
||
| Active, not recruiting |
NCT01723202 -
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT05500508 -
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02568267 -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
|
Phase 2 | |
| Unknown status |
NCT02140476 -
Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy
|
N/A | |
| Recruiting |
NCT06286631 -
Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale
|
||
| Completed |
NCT06325787 -
Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma
|
N/A | |
| Terminated |
NCT01974284 -
Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma
|
N/A | |
| Active, not recruiting |
NCT00984191 -
Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid
|
N/A | |
| Active, not recruiting |
NCT04731467 -
A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05668962 -
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
|
Phase 2 | |
| Completed |
NCT02178345 -
Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer
|
||
| Not yet recruiting |
NCT06133374 -
Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples
|
||
| Completed |
NCT03470259 -
Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging
|
Phase 1 | |
| Active, not recruiting |
NCT04129411 -
Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
|
N/A |